The antihypertension drug doxazosin inhibits tumor growth and angiogenesis by decreasing VEGFR-2/Akt/mTOR signaling and VEGF and HIF-1α expression

Doxazosin is an α1 adrenergic receptor blocker that also exerts antitumor effects. However, the underlying mechanisms by which it modulates PI3K/Akt intracellular signaling are poorly understood. In this study, we reveal that doxazosin functions as a novel antiangiogenic agent by inhibiting vascular endothelial growth factor (VEGF)-induced cell migration and proliferation. It also inhibited VEGF-induced capillary-like structure tube formation in vitro. Doxazosin inhibited the phosphorylation of VEGF receptor-2 (VEGFR-2) and downstream signaling, including PI3K, Akt, 3-phosphoinositide-dependent protein kinase 1 (PDK1), mammalian target of rapamycin (mTOR), and hypoxia-inducible factor 1 (HIF-1α). However, it had no effect on VEGF-induced extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation. Furthermore, doxazosin reduced tumor growth and suppressed tumor vascularization in a xenograft human ovarian cancer model. These results provide evidence that doxazosin functions in the endothelial cell system to modulate angiogenesis by inhibiting Akt and mTOR phosphorylation and interacting with VEGFR-2.

[1]  Satoru Takahashi,et al.  Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. , 2011, Biological & pharmaceutical bulletin.

[2]  B. Jiang,et al.  AKT signaling in regulating angiogenesis. , 2008, Current cancer drug targets.

[3]  P. Silver,et al.  Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis. , 2007, Blood.

[4]  Bing-Hua Jiang,et al.  Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. , 2006, Cellular signalling.

[5]  Xianglin Shi,et al.  Regulation of angiogenesis and tumor growth by p110 Alpha and AKT1 via VEGF expression , 2006, Journal of cellular physiology.

[6]  Napoleone Ferrara,et al.  Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.

[7]  N. Rahimi,et al.  Substitution of C-terminus of VEGFR-2 with VEGFR-1 promotes VEGFR-1 activation and endothelial cell proliferation , 2004, Oncogene.

[8]  N. Kyprianou,et al.  The role of α-blockers in the management of prostate cancer , 2004 .

[9]  Raymond M. Kraus,et al.  Circulating plasma VEGF response to exercise in sedentary and endurance-trained men. , 2004, Journal of applied physiology.

[10]  N. Kyprianou,et al.  Quinazoline-based α1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-β signalling and IκBα induction , 2003, British Journal of Cancer.

[11]  N. Rahimi,et al.  Comparative Structure‐Function Analysis of VEGFR‐1 and VEGFR‐2 , 2003, Annals of the New York Academy of Sciences.

[12]  N. Kyprianou,et al.  Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2. , 2003, The Journal of urology.

[13]  Napoleone Ferrara,et al.  VEGF and the quest for tumour angiogenesis factors , 2002, Nature Reviews Cancer.

[14]  Jie Du,et al.  Phosphatidylinositol 3-kinase activity is required for epidermal growth factor to suppress proteolysis. , 2002, Journal of the American Society of Nephrology : JASN.

[15]  N. Kyprianou,et al.  Quinazoline-derived α1-Adrenoceptor Antagonists Induce Prostate Cancer Cell Apoptosis Via an α1-Adrenoceptor-independent Action , 2002 .

[16]  N. Ferrara.  Role of vascular endothelial growth factor in regulation of physiological angiogenesis. , 2001, American journal of physiology. Cell physiology.

[17]  Daniel A. Pollard,et al.  Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85α , 2000, Nature Genetics.

[18]  Y. G. Kwon,et al.  Sphingosine 1-phosphate induces angiogenesis: its angiogenic action and signaling mechanism in human umbilical vein endothelial cells. , 1999, Biochemical and biophysical research communications.

[19]  M. Oda,et al.  Tumor angiogenesis and recurrence in stage I non-small cell lung cancer. , 1999, The Annals of thoracic surgery.

[20]  M. Mizumoto,et al.  Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. , 1998, British Journal of Cancer.

[21]  M. Scheid,et al.  Downstream signalling events regulated by phosphatidylinositol 3-kinase activity. , 1998, Cellular signalling.

[22]  R. Kirby,et al.  Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia: past, present and future. , 1997, British journal of urology.

[23]  L. Twiggs,et al.  Vascular endothelial growth factor expression in early stage ovarian carcinoma , 1997, Cancer.

[24]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[25]  D. Gomez,et al.  Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. , 1996, Cancer research.

[26]  M. Shibuya,et al.  Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[27]  M. Shibuya,et al.  Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. , 2013, Journal of biochemistry.

[28]  S. Rho,et al.  Programmed cell death 6 (PDCD6) inhibits angiogenesis through PI3K/mTOR/p70S6K pathway by interacting of VEGFR-2. , 2012, Cellular signalling.

[29]  S. Rho,et al.  A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3K)/AKT pathway in ovarian cancer cells. , 2011, Gynecologic oncology.

[30]  J. B. Garrison,et al.  Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. , 2006, Cancer research.

[31]  L. Nifong,et al.  Angiogenic growth factor response to acute systemic exercise in human skeletal muscle. , 2004, Journal of applied physiology.

[32]  G. Breier.  Endothelial receptor tyrosine kinases involved in blood vessel development and tumor angiogenesis. , 2000, Advances in experimental medicine and biology.

[33]  S. Ramakrishnan,et al.  Vascular permeability factor gene expression in normal and neoplastic human ovaries. , 1994, Cancer research.